Dasatinib Patent Expiration

Dasatinib is Used for treating protein tyrosine kinase-associated disorders and various types of cancer, including chronic myelogenous leukemia. It was first introduced by Bristol Myers Squibb Co in its drug Sprycel on Jun 28, 2006. Another drug containing Dasatinib is Phyrago. 3 different companies have introduced drugs containing Dasatinib.


Dasatinib Patents

Given below is the list of patents protecting Dasatinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Phyrago US11202778 Amorphous solid dispersions of dasatinib and uses thereof Jan 22, 2041 Nanocopoeia
Phyrago US11298356 Amorphous solid dispersions of dasatinib and uses thereof Jan 22, 2041 Nanocopoeia
Phyrago US11324745 Amorphous solid dispersions of dasatinib and uses thereof Jan 22, 2041 Nanocopoeia
Sprycel US7491725

(Pediatric)

Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors Sep 28, 2026 Bristol Myers Squibb
Sprycel US7491725 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors Mar 28, 2026 Bristol Myers Squibb
Sprycel US8680103

(Pediatric)

Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors Aug 04, 2025 Bristol Myers Squibb
Sprycel US8680103 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors Feb 04, 2025 Bristol Myers Squibb
Sprycel US6596746

(Pediatric)

Cyclic protein tyrosine kinase inhibitors Dec 28, 2020

(Expired)

Bristol Myers Squibb
Sprycel US7153856

(Pediatric)

Cyclic protein tyrosine kinase inhibitors Oct 28, 2020

(Expired)

Bristol Myers Squibb
Sprycel US7125875

(Pediatric)

Cyclic protein tyrosine kinase inhibitors Oct 13, 2020

(Expired)

Bristol Myers Squibb
Sprycel US6596746 Cyclic protein tyrosine kinase inhibitors Jun 28, 2020

(Expired)

Bristol Myers Squibb
Sprycel US7153856 Cyclic protein tyrosine kinase inhibitors Apr 28, 2020

(Expired)

Bristol Myers Squibb
Sprycel US7125875 Cyclic protein tyrosine kinase inhibitors Apr 13, 2020

(Expired)

Bristol Myers Squibb



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dasatinib's patents.

Given below is the list recent legal activities going on the following patents of Dasatinib.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 06 Aug, 2020 US7491725
Payment of Maintenance Fee, 12th Year, Large Entity 14 Jun, 2018 US7153856(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 12 Apr, 2018 US7125875
Post Issue Communication - Certificate of Correction 22 Nov, 2011 US7491725
Email Notification 03 Aug, 2010 US7491725
Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Allowance 28 Jul, 2010 US7491725
Record a Petition Decision of Granted for Patent Term Adjustment after Allowance 27 Jul, 2010 US7491725
Adjustment of PTA Calculation by PTO 27 Jul, 2010 US7491725
Court Processing Terminated 23 Jun, 2010 US7491725
Decision in Civil Action - Dismissed by Court 23 Jun, 2010 US7491725


Dasatinib's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Dasatinib Generics

Several generic applications have been filed for Dasatinib.

Given below is the list of companies who have filed for Dasatinib generic.


1. APOTEX

Apotex Inc has filed for 6 different strengths of generic version for Dasatinib. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20MG tablet Prescription ORAL AB Jun 10, 2016
50MG tablet Prescription ORAL AB Jun 10, 2016
70MG tablet Prescription ORAL AB Jun 10, 2016
100MG tablet Prescription ORAL AB Jun 10, 2016
80MG tablet Prescription ORAL AB Nov 23, 2021
140MG tablet Prescription ORAL AB Nov 23, 2021